The Effectiveness of Continuous Ketamine Infusion (KONTINUE)

Effectiveness of Continuous Ketamine Infusion Associated With Magnesium Sulfate for Management of Patient With Chronic Pain : a Prospective Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06131970

Acronym

KONTINUE

Enrollment

Registered

2023-11-15

Start date

2022-02-22

Completion date

2024-08-06

Last updated

2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Keywords

Pain, Neuropathic pain, Chronic pain, Fibromyalgia, Musculoskeletal diseases

Brief summary

There are different treatment for chronic pain. One possible treatment is intravenous infusions of ketamine.

Detailed description

Ketamine continuous intravenous infusion for 4 days in Hospital with 0.5 mg/kg/day associated with Magnesium Sulfate 1000mg/day. Evaluation schedules will be performed at day 15,30 and 60.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Pain lasting for more than six months without contraindication to treatment

Exclusion criteria

* Inability to give consent * Severe psychiatric disorder

Design outcomes

Primary

Measure	Time frame	Description
Long-term effectiveness	1 month	Improvement of the numerical scale - score 0 to 10 - 10 is the worst

Secondary

Measure	Time frame	Description
Pain relief	15, 30, 60 days	Neuropathic Pain Symptom Inventory (NPSI) - score 0 to 10 - 10 is the worst
Variation of quality of life	15, 30, 60 days	Short Form 12 health survey

Countries

Monaco

Outcome results